The U.S. Food and Drug Administration (FDA) has approved it to improve wakefulness in adults with EDS associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD).

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

Taking the drug at bedtime allows patients to ... the first non-controlled substance for the treatment of narcolepsy. This initial approval was only for treatment of excessive daytime sleepiness.

Wakix (pitolisant) was first approved in August 2019 for treatment of excessive sleepiness in adults with narcolepsy. It is the only FDA-approved drug to treat cataplexy associated with narcolepsy ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...